Quantifying the lifetime economic impact of pediatric oral nutritional supplements

Kyi-Sin Than1, Khounish Sharma1, Kirk W Kerr2

  • 1FTI Consulting, Center for Healthcare Economics and Policy, Los Angeles, CA, USA.

Insights

Oral nutritional supplements (ONS) for children at risk of undernutrition in India significantly improve health and economic outcomes. This intervention offers a substantial return on investment, highlighting its value in public health strategies.

Area of Science:

  • Public Health
  • Health Economics
  • Pediatric Nutrition

Background:

  • Pediatric malnutrition is a critical global health issue, especially in low- and middle-income countries.
  • This study evaluates the economic impact of pediatric oral nutritional supplements (ONS) for undernourished children.

Purpose of the Study:

  • To quantify the lifetime, per-person economic impact of pediatric ONS for children at risk of undernutrition in India.
  • To assess the health and economic benefits of ONS interventions.

Main Methods:

  • A decision tree model was used to analyze health and economic outcomes in Indian children.
  • Key outcomes included height-for-age Z-score (HAZ), morbidity, lifetime earnings, and quality-adjusted life-years (QALYs).
  • A lifetime perspective with a 3% discount rate was applied.

Main Results:

  • Pediatric ONS increased mean HAZ by 0.125, improving health outcomes by 0.28 QALYs ($1,019 per person).
  • Lifetime economic earnings increased by $471 per person.
  • The total lifetime incremental value was $1,281 per person, with an estimated 5.63% internal rate of return.

Conclusions:

  • Pediatric ONS are predicted to enhance both quality-of-life and economic prospects for undernourished Indian children.
  • Integrating nutritional interventions like ONS into public health strategies is crucial for addressing childhood undernutrition.
  • Findings have significant implications for global health policy and nutritional interventions.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
821
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
352
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
497
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
388
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
868
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
77